| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Islets of Langerhans Transplantation | 47 | 2024 | 244 | 15.110 |
Why?
|
| Pancreatitis, Chronic | 12 | 2023 | 61 | 4.580 |
Why?
|
| Islets of Langerhans | 22 | 2024 | 555 | 4.500 |
Why?
|
| Pancreatectomy | 20 | 2024 | 164 | 4.420 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2024 | 574 | 3.490 |
Why?
|
| T-Lymphocytes, Regulatory | 12 | 2016 | 335 | 2.490 |
Why?
|
| Transplantation, Autologous | 18 | 2024 | 355 | 1.870 |
Why?
|
| Insulin | 17 | 2023 | 1168 | 1.800 |
Why?
|
| Insulin-Secreting Cells | 13 | 2021 | 430 | 1.720 |
Why?
|
| Blood Glucose | 12 | 2021 | 855 | 1.570 |
Why?
|
| Vascularized Composite Allotransplantation | 2 | 2021 | 17 | 1.410 |
Why?
|
| C-Peptide | 9 | 2021 | 184 | 1.180 |
Why?
|
| Fasting | 2 | 2018 | 167 | 1.120 |
Why?
|
| Pancreas | 8 | 2018 | 252 | 1.030 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 2018 | 192 | 0.920 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2016 | 461 | 0.830 |
Why?
|
| Sulfonamides | 2 | 2023 | 327 | 0.820 |
Why?
|
| Transplant Recipients | 2 | 2021 | 152 | 0.790 |
Why?
|
| Humans | 77 | 2024 | 92352 | 0.790 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 989 | 0.780 |
Why?
|
| Receptors, Interleukin-8A | 2 | 2021 | 5 | 0.770 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2021 | 7 | 0.770 |
Why?
|
| Composite Tissue Allografts | 1 | 2021 | 10 | 0.740 |
Why?
|
| Forkhead Transcription Factors | 6 | 2016 | 177 | 0.710 |
Why?
|
| Cell Separation | 3 | 2020 | 203 | 0.710 |
Why?
|
| Fatty Liver | 1 | 2021 | 101 | 0.640 |
Why?
|
| Diabetes Mellitus | 5 | 2021 | 760 | 0.590 |
Why?
|
| Biological Products | 1 | 2021 | 171 | 0.580 |
Why?
|
| Organ Transplantation | 1 | 2022 | 288 | 0.570 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 121 | 0.570 |
Why?
|
| Donor Selection | 2 | 2018 | 79 | 0.560 |
Why?
|
| Male | 37 | 2024 | 43929 | 0.550 |
Why?
|
| Adult | 28 | 2024 | 27547 | 0.540 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 361 | 0.540 |
Why?
|
| Middle Aged | 24 | 2024 | 27045 | 0.540 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 380 | 0.530 |
Why?
|
| Leukapheresis | 1 | 2016 | 20 | 0.530 |
Why?
|
| Liver Transplantation | 3 | 2021 | 1186 | 0.510 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 225 | 0.510 |
Why?
|
| Pain, Postoperative | 2 | 2018 | 274 | 0.490 |
Why?
|
| Graft Survival | 3 | 2018 | 935 | 0.490 |
Why?
|
| Cell Culture Techniques | 2 | 2014 | 199 | 0.480 |
Why?
|
| Tissue Preservation | 1 | 2015 | 15 | 0.470 |
Why?
|
| Transplantation Tolerance | 3 | 2011 | 142 | 0.440 |
Why?
|
| Universities | 1 | 2015 | 148 | 0.430 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3776 | 0.430 |
Why?
|
| Body Height | 1 | 2014 | 102 | 0.430 |
Why?
|
| Female | 29 | 2024 | 47901 | 0.420 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 696 | 0.420 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2013 | 51 | 0.410 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2013 | 6 | 0.410 |
Why?
|
| Ikaros Transcription Factor | 1 | 2013 | 25 | 0.400 |
Why?
|
| Cryopreservation | 1 | 2013 | 72 | 0.390 |
Why?
|
| Quality of Life | 3 | 2018 | 1745 | 0.390 |
Why?
|
| Treatment Outcome | 13 | 2024 | 8730 | 0.390 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 5 | 2016 | 36 | 0.380 |
Why?
|
| United States | 7 | 2022 | 7367 | 0.370 |
Why?
|
| Adolescent | 13 | 2020 | 9495 | 0.360 |
Why?
|
| Immunologic Factors | 1 | 2013 | 175 | 0.360 |
Why?
|
| Pancreatitis | 3 | 2021 | 86 | 0.350 |
Why?
|
| Interferon-gamma | 2 | 2011 | 455 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 351 | 0.330 |
Why?
|
| Prospective Studies | 8 | 2024 | 4474 | 0.330 |
Why?
|
| Child | 11 | 2023 | 7309 | 0.310 |
Why?
|
| Young Adult | 9 | 2020 | 6629 | 0.300 |
Why?
|
| DNA, Catalytic | 1 | 2007 | 2 | 0.280 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 4 | 2016 | 9 | 0.280 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 46 | 0.280 |
Why?
|
| Animals | 25 | 2021 | 28059 | 0.280 |
Why?
|
| Tunica Intima | 1 | 2007 | 60 | 0.280 |
Why?
|
| Vas Deferens | 1 | 2007 | 8 | 0.270 |
Why?
|
| Genital Diseases, Male | 1 | 2007 | 9 | 0.270 |
Why?
|
| Obesity | 2 | 2019 | 1014 | 0.260 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 764 | 0.260 |
Why?
|
| Tissue Scaffolds | 3 | 2017 | 124 | 0.260 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 475 | 0.250 |
Why?
|
| Surgical Mesh | 1 | 2007 | 124 | 0.240 |
Why?
|
| Hernia, Inguinal | 1 | 2007 | 75 | 0.240 |
Why?
|
| Time Factors | 6 | 2020 | 5431 | 0.230 |
Why?
|
| Rats | 11 | 2017 | 4073 | 0.220 |
Why?
|
| Glucose Tolerance Test | 2 | 2018 | 232 | 0.210 |
Why?
|
| Chicago | 2 | 2021 | 1463 | 0.210 |
Why?
|
| Pancreatic Polypeptide-Secreting Cells | 2 | 2013 | 5 | 0.210 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 41 | 0.200 |
Why?
|
| North America | 2 | 2018 | 189 | 0.200 |
Why?
|
| Body Mass Index | 2 | 2019 | 799 | 0.200 |
Why?
|
| Polyneuropathies | 1 | 2023 | 26 | 0.200 |
Why?
|
| Registries | 3 | 2012 | 903 | 0.200 |
Why?
|
| Tetrabenazine | 3 | 2008 | 3 | 0.200 |
Why?
|
| Glucagon-Secreting Cells | 3 | 2018 | 26 | 0.190 |
Why?
|
| Rats, Inbred Lew | 7 | 2016 | 205 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1761 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 408 | 0.190 |
Why?
|
| Transplantation, Heterologous | 2 | 2021 | 369 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 137 | 0.180 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 1804 | 0.170 |
Why?
|
| Acute Disease | 3 | 2021 | 855 | 0.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 66 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 1211 | 0.170 |
Why?
|
| Transplantation | 1 | 2020 | 38 | 0.170 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 154 | 0.170 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 361 | 0.170 |
Why?
|
| Glucose | 3 | 2014 | 683 | 0.170 |
Why?
|
| Double-Blind Method | 2 | 2021 | 1755 | 0.160 |
Why?
|
| Ampulla of Vater | 1 | 2019 | 23 | 0.160 |
Why?
|
| Alcoholism | 1 | 2021 | 185 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2021 | 9694 | 0.160 |
Why?
|
| Recurrence | 3 | 2021 | 1180 | 0.160 |
Why?
|
| Anxiety | 1 | 2021 | 324 | 0.150 |
Why?
|
| Mice, Nude | 1 | 2021 | 825 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1398 | 0.150 |
Why?
|
| Logistic Models | 2 | 2021 | 1239 | 0.150 |
Why?
|
| Cell Transplantation | 2 | 2017 | 48 | 0.150 |
Why?
|
| Organ Size | 3 | 2014 | 374 | 0.150 |
Why?
|
| Aged | 9 | 2021 | 19953 | 0.150 |
Why?
|
| Tissue Donors | 2 | 2016 | 531 | 0.150 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 107 | 0.150 |
Why?
|
| Mice | 10 | 2021 | 12133 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2021 | 2454 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2021 | 2979 | 0.140 |
Why?
|
| Abdominal Pain | 2 | 2021 | 144 | 0.140 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 48 | 0.140 |
Why?
|
| Cells, Cultured | 5 | 2016 | 2903 | 0.140 |
Why?
|
| Depression | 1 | 2021 | 526 | 0.130 |
Why?
|
| Smoking | 1 | 2021 | 640 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 556 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2017 | 337 | 0.130 |
Why?
|
| Cell Differentiation | 3 | 2014 | 1607 | 0.130 |
Why?
|
| Biotin | 2 | 2014 | 45 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2017 | 190 | 0.130 |
Why?
|
| Sodium Compounds | 1 | 2016 | 3 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 3 | 2017 | 145 | 0.130 |
Why?
|
| Aluminum Compounds | 1 | 2016 | 6 | 0.130 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 10 | 0.130 |
Why?
|
| Ultrafiltration | 1 | 2016 | 13 | 0.130 |
Why?
|
| Transplantation, Homologous | 4 | 2013 | 1015 | 0.130 |
Why?
|
| Polyvinyls | 1 | 2016 | 21 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2014 | 57 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 407 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2016 | 707 | 0.130 |
Why?
|
| Positron-Emission Tomography | 2 | 2009 | 342 | 0.120 |
Why?
|
| Pain Management | 1 | 2017 | 154 | 0.120 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2016 | 46 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 576 | 0.120 |
Why?
|
| Heart Transplantation | 3 | 2008 | 774 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 329 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 315 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 786 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2018 | 377 | 0.120 |
Why?
|
| Cell Proliferation | 4 | 2016 | 1720 | 0.120 |
Why?
|
| Hospitalization | 1 | 2021 | 925 | 0.120 |
Why?
|
| Pancreas Transplantation | 2 | 2024 | 104 | 0.120 |
Why?
|
| Pancreatic Ducts | 1 | 2014 | 30 | 0.110 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2014 | 31 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2021 | 767 | 0.110 |
Why?
|
| Pentanoic Acids | 1 | 2014 | 6 | 0.110 |
Why?
|
| Incidence | 1 | 2019 | 1661 | 0.110 |
Why?
|
| Biomarkers | 3 | 2016 | 1847 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 605 | 0.110 |
Why?
|
| Graft Rejection | 4 | 2010 | 1110 | 0.110 |
Why?
|
| Pancreatic Hormones | 1 | 2014 | 15 | 0.110 |
Why?
|
| Surface-Active Agents | 1 | 2014 | 60 | 0.110 |
Why?
|
| Receptors, Immunologic | 3 | 2018 | 142 | 0.110 |
Why?
|
| Glucose Intolerance | 1 | 2014 | 99 | 0.110 |
Why?
|
| Contraindications | 1 | 2014 | 70 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2010 | 628 | 0.110 |
Why?
|
| Protein Precursors | 1 | 2014 | 138 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6918 | 0.100 |
Why?
|
| Tissue Engineering | 2 | 2017 | 198 | 0.100 |
Why?
|
| Uracil | 1 | 2013 | 55 | 0.100 |
Why?
|
| Morphogenesis | 1 | 2014 | 206 | 0.100 |
Why?
|
| Serum | 1 | 2013 | 25 | 0.100 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 75 | 0.100 |
Why?
|
| Body Weight | 1 | 2014 | 456 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 93 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 205 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2037 | 0.090 |
Why?
|
| Piperidines | 1 | 2013 | 164 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 1247 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 205 | 0.090 |
Why?
|
| Prognosis | 2 | 2018 | 3872 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2014 | 497 | 0.090 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 8 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2016 | 3806 | 0.090 |
Why?
|
| Vesicular Monoamine Transport Proteins | 2 | 2008 | 3 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2013 | 473 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2013 | 1270 | 0.090 |
Why?
|
| Risk Factors | 4 | 2024 | 5708 | 0.090 |
Why?
|
| Mice, SCID | 3 | 2018 | 265 | 0.080 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2010 | 30 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 2010 | 0.080 |
Why?
|
| Portal System | 1 | 2009 | 13 | 0.080 |
Why?
|
| Transplantation, Isogeneic | 1 | 2009 | 40 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 999 | 0.080 |
Why?
|
| Patient Selection | 1 | 2014 | 689 | 0.080 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 21 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 887 | 0.080 |
Why?
|
| Nanostructures | 1 | 2010 | 82 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2685 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 291 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 800 | 0.080 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2008 | 9 | 0.070 |
Why?
|
| Rats, Mutant Strains | 1 | 2007 | 23 | 0.070 |
Why?
|
| Injections, Intra-Arterial | 1 | 2007 | 33 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 66 | 0.070 |
Why?
|
| Neutrophils | 1 | 2009 | 323 | 0.070 |
Why?
|
| Rats, Inbred Strains | 1 | 2007 | 311 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 67 | 0.070 |
Why?
|
| Fibrin | 1 | 2007 | 86 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2009 | 476 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1232 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 2394 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 697 | 0.060 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 775 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 355 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2010 | 2793 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1733 | 0.060 |
Why?
|
| Biocompatible Materials | 2 | 2017 | 197 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1480 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2450 | 0.060 |
Why?
|
| Canada | 1 | 2006 | 205 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2016 | 3505 | 0.060 |
Why?
|
| Cell Adhesion | 2 | 2017 | 431 | 0.060 |
Why?
|
| Actins | 1 | 2007 | 469 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 142 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2004 | 114 | 0.050 |
Why?
|
| Vitamin A | 1 | 2023 | 28 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 68 | 0.050 |
Why?
|
| Neural Conduction | 1 | 2023 | 71 | 0.050 |
Why?
|
| Thinness | 1 | 2023 | 46 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 169 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 206 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 3376 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 693 | 0.050 |
Why?
|
| Vitamins | 1 | 2023 | 84 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 112 | 0.050 |
Why?
|
| Tissue Survival | 2 | 2014 | 13 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 282 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 863 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 283 | 0.040 |
Why?
|
| Diet | 1 | 2024 | 448 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2020 | 13 | 0.040 |
Why?
|
| Pancreatic Diseases | 1 | 2020 | 56 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 71 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 76 | 0.040 |
Why?
|
| Gene Expression | 2 | 2014 | 1312 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 211 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 2009 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2003 | 478 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 311 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 234 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 114 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 867 | 0.040 |
Why?
|
| Alloxan | 1 | 2018 | 3 | 0.040 |
Why?
|
| Dependovirus | 1 | 2018 | 35 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2014 | 726 | 0.030 |
Why?
|
| Glucagon | 1 | 2018 | 113 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 146 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 87 | 0.030 |
Why?
|
| Phenotype | 2 | 2016 | 2503 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 448 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 270 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2016 | 66 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2004 | 1688 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2018 | 176 | 0.030 |
Why?
|
| Absorption, Physicochemical | 1 | 2016 | 1 | 0.030 |
Why?
|
| Chemical Precipitation | 1 | 2016 | 18 | 0.030 |
Why?
|
| Charcoal | 1 | 2016 | 13 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 307 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 360 | 0.030 |
Why?
|
| Membranes, Artificial | 1 | 2016 | 37 | 0.030 |
Why?
|
| Dioxoles | 1 | 2016 | 8 | 0.030 |
Why?
|
| Materials Testing | 1 | 2016 | 94 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 161 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 790 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 438 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1094 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2016 | 278 | 0.030 |
Why?
|
| Pancreatic Function Tests | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 488 | 0.030 |
Why?
|
| Somatostatin-Secreting Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 444 | 0.030 |
Why?
|
| Benzamides | 1 | 2016 | 239 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2014 | 18 | 0.030 |
Why?
|
| Succinimides | 1 | 2014 | 12 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 807 | 0.030 |
Why?
|
| Streptavidin | 1 | 2014 | 14 | 0.030 |
Why?
|
| Myocardium | 1 | 2017 | 586 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 793 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 1006 | 0.030 |
Why?
|
| Rats, Inbred WF | 2 | 2004 | 11 | 0.030 |
Why?
|
| Rats, Inbred ACI | 2 | 2004 | 25 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1904 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 102 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 81 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 559 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 332 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 205 | 0.030 |
Why?
|
| Ethanol | 1 | 2016 | 262 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 419 | 0.030 |
Why?
|
| Streptozocin | 1 | 2013 | 55 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2014 | 177 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 62 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 2504 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 129 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 607 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 311 | 0.020 |
Why?
|
| Cytokines | 1 | 2016 | 842 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 278 | 0.020 |
Why?
|
| Protein Transport | 1 | 2014 | 430 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2016 | 441 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 259 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1500 | 0.020 |
Why?
|
| Regeneration | 1 | 2013 | 157 | 0.020 |
Why?
|
| Sirolimus | 1 | 2013 | 175 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 753 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2013 | 373 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 299 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2368 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2011 | 81 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 1593 | 0.020 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2010 | 19 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 45 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 702 | 0.020 |
Why?
|
| Immobilized Proteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 2075 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 161 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2011 | 107 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 131 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 66 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2010 | 102 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 974 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 250 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2730 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 273 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 3023 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2010 | 187 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 225 | 0.020 |
Why?
|
| Perfusion | 1 | 2010 | 261 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 901 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 560 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 441 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2010 | 317 | 0.020 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 10 | 0.020 |
Why?
|
| Levodopa | 1 | 2008 | 38 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 407 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 3206 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1900 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2006 | 35 | 0.020 |
Why?
|
| Dopamine | 1 | 2008 | 274 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 863 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1960 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1512 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 195 | 0.010 |
Why?
|
| Vesicular Biogenic Amine Transport Proteins | 1 | 2004 | 2 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2004 | 89 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2004 | 213 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2003 | 73 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2003 | 85 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 523 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2003 | 173 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1016 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2004 | 360 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 266 | 0.010 |
Why?
|